Lawmakers in the United Kingdom voted recently to allow fertility clinics to use mitochondrial manipulation technology (MMT) to enable women with mutations in mitochondrial genes to have genetically healthy children . But the US Food and Drug Administration (FDA) is being much more conservative and is awaiting results of further preclinical research before allowing clinical trials to begin. The technology is of concern because it manipulates the germline, something many countries prohibit.